Deans' stroke musings: Health Canada Approves XEOMIN (IncobotulinumtoxinA) for Treatment of Post-Stroke Lower Limb Spasticity

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, December 21, 2024

Health Canada Approves XEOMIN (IncobotulinumtoxinA) for Treatment of Post-Stroke Lower Limb Spasticity

This is the whole problem with spasticity; TREATING, NOT CURING! Don't we have anyone in stroke smart enough to cure spasticity? Instead we get the infuriating opinion of Dr. William M. Landau that seems to have short-circuited spasticity research. Schadenfreude can't come soon enough for him.

Spasticity After Stroke: Why Bother? Aug. 2004)

The latest here:

Health Canada Approves XEOMIN (IncobotulinumtoxinA) for Treatment of Post-Stroke Lower Limb Spasticity

XEOMIN® (incobotulinumtoxinA) got approval from Health Canada for treating spasticity in adults in the post-stroke lower limb. A significant step in healthcare history for Canada, this is yet another vital milestone in the wider application for XEOMIN, through which healthcare providers can eventually treat upper and lower limb spasticity in the same patient by combining the two limbs into a total of 600 units. With this label expansion for XEOMIN, its basal role is now underpinned as a fundamental tool in neurological rehabilitation improvement(NOT GOOD ENOUGH! Survivors want 100% recovery! GET THERE!) of ambulation to a reduction in pain. Every year, more than 109,000 strokes adversely affect Canadians. Of this number, a greater percentage of survivors become spastic one year after their stroke. This would be the sixth therapeutic use added to XEOMIN in Canada after others such as cervical dystonia, upper limb spasticity, and chronic sialorrhea.